Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_assertion type Assertion NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_head.
- NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_assertion description "[Amplification of the topo-II gene was seen in 1/7 (14%) CR and in 3/21 (14%) PD to a taxane-based CT. Topo-II protein was overexpressed in 6/11 (55%) CR and in 2/17 (12%) PD to anthracyclines, while in the control group, overexpression was seen in 5/7 (71%) CR and 8/20 (40%) PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_provenance.
- NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_assertion evidence source_evidence_literature NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_provenance.
- NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_assertion SIO_000772 14654958 NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_provenance.
- NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_assertion wasDerivedFrom befree-2016 NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_provenance.
- NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_assertion wasGeneratedBy ECO_0000203 NP423307.RAgZLVUt-z16svQomUI68U2ykoldsmyCq2m1rbLnFyPbs130_provenance.